Search

Author/Creator Bakalos, G.

1. A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B. Issue 5 (29th June 2018)

Authors:
Chan, H. L. Y.; Messinger, D.; Papatheodoridis, G. V.; Cornberg, M.; Xie, Q.; Piratvisuth, T.; Ren, H.; Kennedy, P. T.; Thompson, A.; Caputo, A.; Bakalos, G.; Pavlovic, V.; Lampertico, P.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 48:Issue 5(2018)
Page Start:
547
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A network meta‐analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. (20th August 2013)

Authors:
Hadjigeorgiou, G. M.; Doxani, C.; Miligkos, M.; Ziakas, P.; Bakalos, G.; Papadimitriou, D.; Mprotsis, T.; Grigoriadis, N.; Zintzaras, E.
Journal:
Journal of clinical pharmacy and therapeutics
Issue:
Volume 38:Number 6(2013:Dec.)
Page Start:
433
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Responses are durable for up to 5 years after completion of peginterferon alfa‐2a treatment in hepatitis B e antigen‐positive patients. Issue 9 (9th March 2018)

Authors:
Chuang, W.‐L.; Jia, J.; Chan, H. L. Y.; Han, K.‐H.; Tanwandee, T.; Tan, D.; Chen, X.; Gane, E.; Piratvisuth, T.; Chen, L.; Xie, Q.; Sung, J. J.‐Y.; Messinger, D.; Wat, C.; Bakalos, G.; Liaw, Y. F.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 47:Issue 9(2018)
Page Start:
1306
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗